IGMIN: We're glad you're here. Please click 'create a new query' if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click 'take me to my Query.'
Welcome to IgMin Research – an Open Access journal uniting Biology, Medicine, and Engineering. We’re dedicated to advancing global knowledge and fostering collaboration across scientific fields.
At IgMin Research, we bridge the frontiers of Biology, Medicine, and Engineering to foster interdisciplinary innovation. Our expanded scope now embraces a wide spectrum of scientific disciplines, empowering global researchers to explore, contribute, and collaborate through open access.
Welcome to IgMin, a leading platform dedicated to enhancing knowledge dissemination and professional growth across multiple fields of science, technology, and the humanities. We believe in the power of open access, collaboration, and innovation. Our goal is to provide individuals and organizations with the tools they need to succeed in the global knowledge economy.
IgMin Publications Inc., Suite 102, West Hartford, CT - 06110, USA
We strive to cultivate connections between disciplines to foster new insights and advancements.
Biography
Dr. AA Harutyunyan is a distinguished researcher at the Scientific Technological Center of Organic and Pharmaceutical Chemistry (STCOPC) of the National Academy of Sciences of the Republic of Armenia (NAS RA). Located at 26 Azatutyan Avenue, Yerevan, Armenia, this institute specializes in the development of scientific and technological bases for organic synthesis, drug manufacturing, and the creation of pharmaceutical substances.
Dr. Harutyunyan has contributed significantly to the field of medicinal chemistry, particularly in the synthesis and study of heterocyclic compounds with potential biological activity. His research focuses on the development of synthetic methods for constructing polycyclic azaheterocycles, which serve as reliable structural bases for the design of new pharmacological agents. Notably, he has authored the article "Benzo[4’,5’]imidazo[2’,1’:6,1]pyrido[2,3-d]pyrimidines: Past and Present," published in IgMin Research in November 2023. This work reviews synthetic approaches to constructing this heterocyclic system and discusses their biological properties.
In addition to his research endeavors, Dr. Harutyunyan is actively involved in the academic community, contributing to the advancement of pharmaceutical sciences in Armenia.
Research Interest
Dr. AA Harutyunyan’s research interests lie primarily in the fields of organic chemistry, pharmaceutical sciences, and medicinal chemistry. He focuses on the design and synthesis of novel heterocyclic compounds, particularly polycyclic azaheterocycles, which have significant potential for use as pharmacological agents. His work includes developing new synthetic methodologies for constructing complex molecular structures with biological activity. Dr. Harutyunyan’s research also delves into the pharmacological properties of these compounds, exploring their potential in treating a variety of diseases. He is particularly interested in the structural modification of organic compounds to enhance their bioactivity and selectivity. Additionally, his work involves investigating the mechanisms through which these compounds exert their effects, aiming to contribute to the development of new, more effective drugs. By focusing on the intersection of chemistry and biology, his research seeks to make advancements in the field of drug discovery and development.
Open Access Policy refers to a set of principles and guidelines aimed at providing unrestricted access to scholarly research and literature. It promotes the free availability and unrestricted use of research outputs, enabling researchers, students, and the general public to access, read, download, and distribute scholarly articles without financial or legal barriers. In this response, I will provide you with an overview of the history and latest resolutions related to Open Access Policy.
Synthetic approaches to the construction of the heterocyclic benzo[4’,5’]imidazo[2’,1’:6,1]pyrido[2,3-d]pyrimidine system based on heterocyclizations of substituted benzimidazoles and a new alternative strategy based on 2,4,6-trisubstituted pyrimidinyl-5-propanoic acids are considered. The latter method has been shown to be a successful addition to previously described methods, since it allows one to bypass the significant limitations associated with the use of substituted benzimidazoles and allows the introduction of fu...nctional substituents at different positions of the heterocycle that are inaccessible by other methods. The available information on derivatives of this heterocyclic system and their biological properties is summarized.
